Floatz logo

Therapeutic Asset Ratings

394 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cyclophosphamide
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLCP3B (60)
Docetaxel
Endometrial Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Docetaxel
Endometrial Cancer
Merck Sharp & Dohme LLCP3B (60)
Epirubicin
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLCP3B (60)
Everolimus
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3B (60)
Favezelimab
Colorectal Cancer
Merck Sharp & Dohme LLCP3B (60)
Favezelimab
Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Ifinatamab Deruxtecan
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Irinotecan
Cervical Cancer
Merck Sharp & Dohme LLCP3B (60)
LENVATINIB
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3B (60)
Lorazepam
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLCP3B (60)
Nivolumab
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3B (60)
Opevesostat
Metastatic Prostate Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Palbociclib
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3B (60)
Patritumab Deruxtecan
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Pembrolizumab
Breast Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Pembrolizumab
Superficial Urinary Bladder Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Solu-Cortef
Castration-Resistant Prostate Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Benadryl
Advanced or Metastatic CRC
Merck Sharp & Dohme LLCP2B (60)
Boserolimab
Triple-Negative Breast Carcinoma
Merck Sharp & Dohme LLCP2B (60)
Efinopegdutide
Metabolic Dysfunction-Associated Steatotic Liver Disease
Merck Sharp & Dohme LLCP2B (60)
Zilovertamab Vedotin
Richter Transformation
Merck Sharp & Dohme LLCP2B (60)
HYDROMORPHON
B-All
Merck Sharp & Dohme LLCP2/3B (60)
Bacillus Calmette-Guerin
Superficial Urinary Bladder Carcinoma
Merck Sharp & Dohme LLCP3B (59)
Docetaxel
Hepatocellular Carcinoma
Merck Sharp & Dohme LLCP3B (59)
Showing 101 to 125 of 394 assets
PreviousPage 5 of 16Next